Middle East And Africa Food For Special Medical Purpose (FSMP) Market Size & Outlook, 2026-2034
Middle East And Africa Food For Special Medical Purpose (FSMP) Market Insights
- Deep Market Insights analysis indicates that the Middle East And Africa Food For Special Medical Purpose (FSMP) Market size, which was USD 1645.11 Million in 2025, is projected to attain USD 2786.56 Million by 2034.
- The market is expected to register a CAGR of 6.05% over the period 2026–2034.
- In 2025, Oral nutritional supplements emerged as the dominant By Product Type based on market size.
- Parenteral nutrition is projected to register the fastest growth, positioning it as the most attractive By Product Type segment over the forecast horizon.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Middle East And Africa held 10.13% share of the global Food For Special Medical Purpose (FSMP) Market size in 2025.
- United States is expected to remain the largest contributor to the global market size by 2034.
- By 2034, Saudi Arabia is anticipated to record the highest growth in Middle East and Africa, with the market size expected to reach USD 639.2 Million.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 1645.11 Million |
| Market Size In 2034 | USD 2786.56 Million |
| Largest segment | Oral nutritional supplements |
| Units | Revenue in USD Million |
| CAGR | 6.05% (2026-2034) |
| Segmnetation Covered | |
| Middle East and Africa |
|
| By Product Type |
|
| By Application |
|
| By Form |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Middle East And Africa Food For Special Medical Purpose (FSMP) Market Country 2026-2034 (USD Million)
| Middle East and Africa | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Arab Emirates | XX.x | XX.x | XX.x | 737.17 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Saudi Arabia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| South Africa | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Egypt | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nigeria | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Turkey | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Middle East And Africa Food For Special Medical Purpose (FSMP) Market By Product Type 2026-2034 (USD Million)
| By Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral nutritional supplements | XX.x | XX.x | XX.x | 754.45 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Enteral nutrition | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Parenteral nutrition | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Disease-specific formulas | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Middle East And Africa Food For Special Medical Purpose (FSMP) Market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | XX.x | XX.x | XX.x | 690.78 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diabetes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Neurological disorders | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gastrointestinal diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Middle East And Africa Food For Special Medical Purpose (FSMP) Market By Form 2026-2034 (USD Million)
| By Form | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Powder | XX.x | XX.x | XX.x | 724.34 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Liquid | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ready-to-drink | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Semi-solid | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Middle East And Africa Food For Special Medical Purpose (FSMP) Market By End User 2026-2034 (USD Million)
| By End User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 662.98 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Home care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Long-term care facilities | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.